Skip to main content

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Terminated · Phase 1, Phase 2 · NCT03648372

Conditions: Neoplasms, Lymphoma, Hematologic Neoplasms

At a glance

Research payments reported, 2025
$15,042
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
109

About the trial

Sponsor
Takeda
Tested
TAK-981 (drug)
Dates
Started 2018-10-01; completion 2023-12-14
Results posted
Yes

This study is in 2 parts. The main aims of the 1st part of the study are to check if people with advanced solid tumors or cancers in the immune system (lymphomas) have side effects from TAK-981, and to check how much TAK-981 they can receive without getting side effects from it. The main aims of the 2nd part of the study are to learn if the condition of people with specific cancers improves after treatment with TAK-981. Another aim is to check for side effects from TAK-981. In the 1st part of the study, participants will receive TAK-981. In the 2nd part of the study, participants with specific tumor types will receive TAK-981 at the recommended phase 2 dose determined during the 1st part …

From ClinicalTrials.gov, last updated 2024-11-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $15,042 in research payments for this study in 2025 (2 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.